Collective Intelligence for Translational Medicine: Crowdsourcing insights and innovation from an interdisciplinary biomedical research community by Budge, Eleanor Jane et al.
1 
Budge et al., 2015 
Collective Intelligence for Translational Medicine: Crowdsourcing insights and 
innovation from an interdisciplinary biomedical research community 
 
Budge E J, Tsoti S M, Howgate D J, Sivakumar S, Jalali M
*
 
 
Eleanor Jane Budge 
1
, Sandra Maria Tsoti 
2
, Daniel James Howgate 
3
, Shivan Sivakumar 
4,5
, Morteza 
Jalali 
6,7,8* 
 
 
1 
Keble College, University of Oxford, Oxford, UK   
2 
Faculty of Medicine, Imperial College London, London, UK. 
3 
Trauma Unit, John Radcliffe Hospital, Oxford, UK. 
4
 Department of Oncology, University of Oxford, Oxford, UK. 
5
 Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, UK. 
6 
Anne McLaren Laboratory for Regenerative Medicine, Wellcome Trust-Medical Research Council 
Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK. 
7 
Department of Plastic and Reconstructive Surgery, Nuffield Orthopaedic Centre, Oxford, UK. 
8
 Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Medical 
Sciences Division, University of Oxford, Oxford, UK. 
 
* 
Corresponding author. 
Dr Morteza Jalali 
Department of Plastic and Reconstructive Surgery 
Nuffield Orthopaedic Centre 
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences 
Medical Sciences Division, University of Oxford 
Windmill Road 
Oxford OX3 7HE UK 
email morteza.jalali@ndorms.ox.ac.uk 
 
2 
Budge et al., 2015 
 
Collective Intelligence for Translational Medicine: Crowdsourcing insights and 
innovation from an interdisciplinary biomedical research community 
 
Abstract 
Translational medicine bridges the gap between discoveries in biomedical science and 
their safe and effective clinical application. Despite the gross opportunity afforded by 
modern technology for unparalleled advances in this field, the process of translation 
remains protracted. Efforts to expedite science translation have included the 
facilitation of interdisciplinary collaboration within both academic and clinical 
environments in order to generate integrated working platforms fueling the sharing of 
knowledge, expertise and tools to align biomedical research with clinical need. 
However, barriers to scientific translation remain and further progress is urgently 
required. Collective intelligence and crowdsourcing applications offer the potential 
for global online networks, allowing connection and collaboration between a wide 
variety of fields. This would drive the alignment of biomedical science with 
biotechnology, clinical need and patient experience to deliver evidence-based 
innovation to revolutionize medical care worldwide. Here we discuss the critical steps 
towards implementing collective intelligence in translational medicine using the 
experience of those in other fields of science and public health.  
 
Key words 
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Key messages 
• The scientific translation of biomedical research into clinical applications is 
protracted, despite the mass opportunity afforded by modern science. 
• Barriers to translational medicine exist as a result of the impracticalities of research, 
organizational hurdles and lack of an interdisciplinary workforce. 
• Collective intelligence and crowdsourcing offer the potential to expedite the 
translational process by providing a platform upon which interdisciplinary workforces 
can collaborate and communicate, aligning biomedical research with clinical need to 
revolutionize healthcare worldwide. 
 
Introduction 
Translational medicine describes the journey of scientific discovery from the 
laboratory bench to the patient bedside and can be used to drive the evolution of 
medical practice and transform healthcare worldwide (1). Translational medicine aims 
to implement evidence-based research toward clinical applications such as novel 
diagnostic techniques, therapeutics, medical devices and implantable materials for 
tissue replacement and also plays a role in the development of public healthcare 
policies. Scientific advances created through research and development have 
increased our understanding of disease pathology, which in turn presents unique 
opportunities to develop and innovate on a greater level than ever before. 
Paradoxically, the translational process remains frustratingly protracted and the 
implementation of basic scientific research findings into clinical practice is too often 
not achieved within a useful and clinically relevant timeframe.  Here we discuss the 
potential impact of the application of collective intelligence and crowdsourcing in 
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translational medicine, and the experience of those doing so in fields outside of 
medicine. 
 
In order to effectively utilize the knowledge gained through cutting-edge scientific 
research, it is essential to understand the current barriers to translational medicine, 
and streamline the process by which clinical applications are established.  
 
In an industry that is becoming increasingly specialised and technologically complex, 
the ability to utilize the collective intelligence of industrial peers is paramount to 
translational efficiency. Since no individual can acquire and apply the knowledge that 
may be provided by a collective audience, as medical treatment becomes more 
personalised, clinical decisions must be more experience and evidence based than 
ever before. Establishing a medium of collaborative communication between 
individual care providers in the translational pathway is essential to this process.  
Furthermore, collective intelligence provides a unique opportunity for the validation 
of emerging novel medical technologies and matching medical product development 
to current market and population health needs (2). 
 
Therefore collective intelligence and crowdsourcing applications are increasingly 
relevant in order to help initiate and facilitate the process of science translation.  
 
Barriers to science translation and present solutions 
 
Identifying the barriers to efficient translation has been a critical and indeed global 
research and development issue for the last decade, gaining much attention from the 
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scientific community (3) (4) (5) (6). Table 1 outlines commonly cited causes for 
stagnation along the pathways of translational science. Here, we have categorized 
barriers into those associated with the practicalities of research, the hurdles generated 
by institutional organisations and limitations with regard to the research workforce.  
 
The influence translational medicine could make on healthcare has also been 
recognized outside the biomedical community. The United Kingdom (UK) 
Government has identified the need to facilitate the progression of this field and has 
proposed a myriad of changes to address barriers presented in table 1. In order to 
alleviate the financial burden of research, amendments to funding applications, tax 
credit schemes, value added tax and cost-sharing exemptions have been suggested. 
Furthermore, concerns over the limiting regulations imposed on researchers have been 
raised and suggestions made as to how to reduce these. Much focus has been directed 
at generating environments in which bioinformatics can be generated and applied in 
clinical-research settings by altering the infrastructure and policies of institutions 
involved in research or clinical practice (7). There have been similar strategies 
employed in the United States (US) (8). 
 
Most notably, Government initiatives have led to the formation of collaborative 
partnerships between universities, hospitals and businesses in the form of multi-
disciplinary centres. These institutions foster an integrated and multi-faculty research 
and development environment; within which clinical directions are aligned and 
expertise shared in order to successfully bring new discoveries into clinical fruition. 
These include the Academic Health Science Centres (AHSCs) and NIHR (National 
Institute for Health Research) Biomedical Research Centres and Units (BRCs and 
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BRUs). This is an internationally recognised model employed by the American 
National Institutes for Health (NIH) in the form of National Centers for Advancing 
Translational Sciences (NCATS).  
 
In order to reap the benefits of interdisciplinary centres, it has been suggested that 
Master’s or Certificates in Advanced Education in Translational Medicine should be 
introduced (9). The courses would provide experience of product development, 
technological management, market positioning and regulation, training advocates in 
translational medicine. Individuals with such skill sets would be able to identify 
metrics of both efficacy assessment and sustainability of translational medicine and 
incentivize direction towards the production of clinical applications (10).  
 
Despite these efforts, issues such as career pathways, academic rewards, differing 
economic incentives, departmental budgets and policies still prevent streamlined 
science translation (11) (12) (13). With these hurdles persisting, a new infrastructure 
is required to take advantage of scientific and technological advances. 
 
Collective intelligence and crowdsourcing 
 
The ubiquitous use of the Internet proffers a new dimension of connection and 
collaboration within the biomedical community.  The use of online networks to enable 
access to the cumulative knowledge of individual contributors is termed collective 
intelligence (CI). Common examples of this model include Wikipedia, YouTube and 
open-source software such as Linux. Actively directing this body of knowledge 
towards a specific creative or practical problem is a tactic known as crowdsourcing 
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(14) (15). These two methods can be used in conjunction with one another. Whilst CI 
increases the capacity for knowledge, crowdsourcing broadens the diversity of input 
and offers exposure to a variety of specialist skills. The paradigms of ‘crowd wisdom’ 
and ‘marginality’ describe the increased insight and creativity brought to a developing 
team through the combination of distinguished cognitive heuristics from multiple 
fields. These attributes have made CI and crowdsourcing methods popular business 
tools (16). By implementing these methods within translational pathways, 
opportunities provided by modern science could be seized to drive unmatched 
advances in medical care. 
 
CI has already been recognized as a successful method in facilitating innovation and 
has been applied within several different industries.  Crowdsourcing instructs the out-
sourcing of large-scale data acquisition from dispersed locations and as a result has 
been employed within the public health domain. The US Geological Society (USUG) 
has developed an earthquake mapping application, ‘Did You Feel it?’ which relies on 
data input from citizens regarding their location and the extent to which they felt the 
tremor. Thus allowing for damage predictions and appropriate disaster relief 
dissemination (17).  
 
The use of web interfaces within the healthcare sector is expanding (18). Personalised 
health care apps which support lifestyle changes such as smoking cessation (19), 
weight loss (20), exercise programs and the management of chronic pain disorders are 
gaining popularity(21). The MyHeartMap Challenge tasks citizens with the 
programming of a dynamic map of defibrillators within the community for emergency 
use, via a smart phone application (22). The success of these applications highlights 
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the acceptance of modern technology within the healthcare domain and supports the 
use of online and technological software within this field.  
 
Despite their use within the healthcare sector, CI and crowdsourcing have not yet 
been fully embraced as a method of improving public health through their application 
within translational medicine.  
 
 
Applications of collective intelligence and crowdsourcing for healthcare 
innovation  
 
Applying the CI of a multi-disciplinary audience and using an online interface to 
procure, present and process data on a large scale through crowd-sourcing 
applications offers a new framework to accelerate translational medicine. The lack of 
geographical, institutional and economic barriers could sanction healthcare 
development worldwide, breeching the long-standing issues that currently impede 
translational progression. These methods can support multi-disciplinary collaboration 
and be directed towards multiple applications from solving empirical research 
problems, to data acquisition and analysis, or education.  
 
Solving empirical research problems 
 
Modern technology has provided the research community with data on a monumental 
scale, for example the Human Genome Project. However empirically provable 
problems often remain unsolved due to time, labor, financial, or political constraints, 
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leaving research questions unanswered.   Crowdsourcing can be used to overcome this 
issue by outsourcing tasks to a specific audience. A notable and successful example is 
Foldit; a project that allows users to help identify the unknown motif of folded 
proteins that can be used to find cures for diseases such as Human Immuno deficiency 
Virus (HIV) and potentially reduce mortality and morbidity worldwide (23).  
 
Similarly, DREAM (Dialogue for Reverse Engineering Assessments and Methods) 
and the non-profit Prize4Life group pioneered a crowdsourcing competition in which 
contributors were challenged with the identification of algorithms to monitor the 
progression of Amytrophic Lateral Sclerosis (ALS), a disease with highly variable 
presentations and progression patterns. The result of this competition was the 
production of thirty-seven unique algorithms, two of which outperformed those 
suggested by ALS clinicians. In addition several potential new biomarkers of disease 
progression were highlighted, further elucidating the pathophysiology behind ALS 
and aiding the diagnosis of ‘fast’ versus ‘slow’ disease types (24). The FoldIt and 
ALS challenge projects demonstrate the potential for crowdsourcing data and 
benefitting from the collective intelligence of an audience, illustrating how these 
methods can be employed to answer empirical research questions and to enhance and 
accelerate science translation.  
 
Data acquisition, access and analysis 
 
Whilst traditional data acquisition can be time and labor intensive, crowdsourcing can 
be used to obtain patient data from diverse, heterogeneous populations. Despite the 
necessity of defined inclusion and exclusion criteria, the subject population involved 
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in clinical trials is often recruited from a small geographical area within the locality of 
the research facility, which depending on the consistency of the population may lead 
to the acquisition of data from an unrepresentative sample population.  The collation 
of data from multiple research centres can overcome this problem to an extent, 
although data acquisition from remote populations but may remain limited.  Using an 
online interface to gather information accelerates data acquisition and provides any 
patient or subject with the opportunity to contribute on a global scale, regardless of 
where they live and what kind of healthcare they have access to. However in this case 
reliable internet access and local motivation to join a trial are limiting factors.  
 
Several studies have compared data collected by traditional face-to-face consultations 
and online crowdsourcing methods (25) (26). These identified the huge potential of 
fast and diverse data retrieval crowdsourcing proffered. Improving the nuances of 
online data acquisition and designing validated outcome measurements to ensure 
accuracy and improve the validity of data provided could lead to the popularisation of 
online clinical trials which accumulate data from an international sample group (27). 
The use of this type of data retrieval lends it self most favorably to subjective data 
collection as this is unaffected by incorrect estimations or incomplete measurements 
of confounders by patient contributors. This would be valuable to both individual 
users and those tasked with informing clinical or health policies in the future and 
could lead to revolutionary change in the format and progression of clinical trials.  
 
Departmentalized institutional silos often limit access to data that has already been 
collated by other research groups. To overcome this online, open-access platforms, 
presenting data submitted from multiple faculties within the biomedical community 
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have been set-up, facilitating the analysis of previously obtained data and reducing the 
costs of research and providing researches access to data they might not be able to 
acquire otherwise.  
 
Several online networks are developing as platforms for open-access data. In the UK 
the Clinical Practice Research Datalink (CPRD) collates primary care data and makes 
it available to researchers. Retrospective, observational cohort analysis studies are 
being conducted on the basis of this data, facilitating the manipulation of one large 
data set for several, unrelated research topics (28) (29). A similar network exists 
across the CTSA collaborations in the US (13).  
 
The Prostate Cancer DREAM challenge was launched with the aim of improving 
predictive models of disease progression and treatment toxicity in prostate cancer by 
mining historical data (30). The data was originally compiled by the Project Data 
Sphere, a collaborative platform committed to providing open–access and analysis of 
historical phase III oncology data sets. The predictions identified through this project 
could reduce the redundancy of historical trial data, aid clinical decisions and improve 
patient outcomes in metastatic prostate cancer patients and exemplifies the role of 
open-access data sourced from a multi-disciplinary contributors in accelerating 
translational medicine.  
 
HipSci, the UK’s induced pluripotent stem cell (iPS) resource is a more specialized 
example that collates genomic, proteomic and cell biology data, thus enabling 
research into the effects of genomic variation of cellular phenotype and provides the 
opportunity to elucidate new disease mechanisms (31) . This data bank has affiliations 
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with the UK’s National Health Service in order to provide corresponding clinical 
information and therefore can be used to develop understanding of genotype on 
disease phenotype and illuminating novel therapeutic approaches.  
 
The pharmaceutical industry has also implemented crowdsourcing applications 
through the generation of public-private partnerships (PPPs), which are designed to 
aid the development of new molecular entities (NMEs) through the collaboration and 
sharing of data. One such partnership, Arch2POCM, uses a widely distributed 
network of biomedical professionals to identify the effects of certain drugs in a phase 
II clinical setting and seeks to establish proof of clinical mechanism (POCM) by 
establishing the molecular interactions of a drug and its effects on a biochemical level 
(32). Importantly, the data is rapidly published and freely available, regardless of 
whether the results are positive or negative and done so without pursuit of patents.  
 
This ‘precompetitive’ method of drug discovery and development supports the 
performance of POCM tests within the public domain, reducing repetition of research 
within separate companies and thereby avoiding economic waste and redundancy of 
expertise time. In addition reduced restrictions can speed up the process and reveal 
the full benefits of certain drugs by validating new therapeutic targets and identifying 
pioneering applications of pre-existing medicines within an industrially sustainable 
model.  
 
The Collaborative Chronic Care Network, C3Nproject, set up by researchers and 
physicians invites patients with inflammatory bowel disease to contribute data online, 
in order to improve the delivery of care and patient experience. The personalized 
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learning system offers three domains: 1) social interaction between contributors, 2) 
technical support for data storage and analysis and 3) an environment to test new 
treatment ideas, and as a result facilitates new therapeutic ideas and improves 
treatment outcomes (33). This is an example of how crowdsourcing data acquisition 
and analysis can be paired with online forums and communication platforms to track 
chronic diseases on a personalised level and refine treatment using real-time data 
from patients, which is then accessible to researchers for future use.  
 
Education  
 
As an increasingly global market, the learning environment can now extend beyond 
the classroom, university lecture theatre and indeed national boundaries. 
Crowdsourcing applications have been used to facilitate medical learning, 
overcoming barriers of location by providing all students with the opportunity to 
observe new techniques and distribute new policies in clinical skills. WebSurg is an 
online library of surgical videos depicting surgical techniques from all specialties. It 
functions as a ‘virtual surgical university’ and aims to encourage integrative learning 
between students, surgeons, anesthetists and nurses, mediating training, information 
distribution and peer review exchanges globally (34). Facilitating inter-professional 
education provides experience of multi-disciplinary relationships and provides 
students with skill sets amenable to collaborative work in the future, which may 
overcome the current limitation of lacking a collaborative translationalist work force.  
 
Academia.edu is a forum upon which researchers can upload their research, track 
other researchers and their work and analyse the impact of their own work within 
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their own field and others. This platform again exemplifies the role for collating inter-
disciplinary data and knowledge with open-access to accentuate learning and 
accelerate scientific translation (35).  
 
Perspectives in Collective Intelligence for Biomedical Science Translation 
 
The evidence supporting the use of CI and crowdsourcing is compelling, however 
many hurdles to their successful application remain. As the scientific and business 
communities continue to embrace these concepts, robust mechanisms to safeguard 
patient data anonymity will become increasingly important in order to allow 
dissemination and use within open-access platforms. Furthermore, diplomacy will be 
required in order to facilitate the integration between public and private sectors, which 
may have conflicting interests regarding the intellectual property of any commercially 
viable advances made through CI.  
 
Conclusions 
 
The recent implementation of crowdsourcing tools into the biomedical research 
community is just beginning to be appreciated; yet its potential is unique. The recent 
and exponential increase in the volume and complexity of clinical data tasks the 
research community to identify a new method of data analysis and necessitates 
networking. In order to facilitate much needed scientific advancement both 
collaboration, communication and comprehensive access to high quality data is 
required. By mediating interdisciplinary networking, platforms collating their 
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collective intelligence can drive the development of new therapeutic options and 
improve the standard of medical care. 
 
The examples discussed in this article represent the growing field of collective 
intelligence and crowdsourcing within biomedical innovation and demonstrate the 
diversity of their application. Using modern technology to mine the collective 
intelligence of research communities and create global networks to reinforce 
connections between stakeholders of the translational pathway can offer a solution to 
the current, reduced efficacy in the bench to bedside journey. Embracing these 
methods promotes a future for successful medical innovation and an opportunity to 
expedite the research-development-dissemination process and improve healthcare 
worldwide, as we enter a new era of medicine.  
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Table I. Current barriers to efficient science translation (13) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type of barrier Barriers to effective translation 
Practicalities of research Difficulty in recruiting volunteers for clinical trials 
Poor outreach and access to minority groups as a volunteer base 
Incompatible data formats between research and clinical databases 
Expenses and lack of funding 
Clinical applications in demand are often not the most economically viable 
Organisational hurdles 
 
 
No co-ordinated inter-disciplinary collaboration  
Departmental budgeting creates barriers to integrative work 
Policies and procedures differ across faculties, industries and borders 
Institutional regulation limits progression 
Collaborative team Lack of qualified ‘translationists’, career pathways and poor career incentives in this area 
Clinical goals of researcher, clinician and developer often do not align 
No designated research time for research-clinicians 
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